Notice of Effectiveness · EFFECT
60 Degrees Pharmaceuticals, Inc.
SXTPNASDAQEQUITYCurrent
Notice of Effectiveness
Company context
60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.
Current securities
Recent company filings
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD Disclosure · Other EventsNov 20, 2026
- 10-Q filingNov 16, 2026
- SCHEDULE 13G/A - filed by INTRACOASTAL CAPITAL, LLC regarding 60 DEGREES PHARMACEUTICALS, INC.Nov 10, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesNov 6, 2026
- Other EventsOct 27, 2026